EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, SinoMab BioScience's enterprise value is HK$2,267.83 Mil.
SinoMab BioScience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.49 Mil. Therefore, SinoMab BioScience's EV-to-Revenue for today is 1,518.98.
The historical rank and industry rank for SinoMab BioScience's EV-to-Revenue or its related term are showing as below:
HKSE:03681'
s EV-to-Revenue Range Over the Past 10 Years
Min: 23.08 Med: 50.99 Max: 1474.47
Current: 1511.62
During the past 7 years, the highest EV-to-Revenue of SinoMab BioScience was 1474.47. The lowest was 23.08. And the median was 50.99.
HKSE:03681's EV-to-Revenue is ranked worse than 96.33% of 1035
companies
in the Biotechnology industry
Industry Median: 7.82
vs HKSE:03681: 1511.62
The historical data trend for SinoMab BioScience's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SinoMab BioScience's EV-to-Revenue
For the Biotechnology subindustry, SinoMab BioScience's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's EV-to-Revenue falls into.
SinoMab BioScience's current Enterprise Value is HK$2,267.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience's share price for today is HK$1.86.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of SinoMab BioScience's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
SinoMab BioScience (HKSE:03681) Business Description
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:03681 has been successfully added to your 